Every Form 4 that CapsoVision, Inc. (CV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CV filings page.
The Harari 2010 Children Remainder Trust - DAH purchased 878,735 shares of CapsoVision, Inc. common stock, and The Harari Descendant's Trust-2012 purchased 878,734 shares, each at $5.6900 per share on September 18, 2026. Eliyahou Harari, identified as a 10% owner, and his wife are trustees of both trusts. No Rule 10b5-1 plan is reported for the purchases.
CapsoVision, Inc. (CV) ten percent owner Shen Ching Hang transferred 3,991,606 common shares on April 17, 2026, from direct ownership to indirect ownership through Star One Global Capital Limited, an entity he wholly owns and controls. The transfer involved no cash or other consideration; his reported direct holdings fell to 0 shares, while the reported indirect position through Star One was 6,400,527 shares after the transfer. The transfer is described as a change in the form of beneficial ownership exempt under Rule 16a-13, and Shen retains sole voting and investment power over the shares held by Star One.
For CapsoVision, Inc. (CV), a Form 4/A amendment corrects the reported beneficial ownership total following a purchase on September 15, 2026. The transaction was an indirect purchase of 878,734 common shares at $5.69 per share through Star One Global Capital Limited; Shen Ching Hang is identified as a ten-percent owner. The corrected post-transaction total is 7,279,261 shares. No Rule 10b5-1 plan is reported.
CapsoVision, Inc (CV) had a Form 4 filed reporting that major shareholder Ching Hang Shen, a ten percent owner, purchased 878,734 shares of common stock on September 15, 2026 at $5.69 per share.
The shares are held indirectly through Star One Global Capital Limited, bringing this indirect position to 2,926,655 shares after the transaction. No Rule 10b5-1 trading plan is reported for this purchase.
CapsoVision, Inc reported that the Harari Family Trust, for which Eliyahou Harari and his wife serve as trustees, purchased 61,068 shares of common stock on 2026-07-17 at $6.73 per share in an open-market or private transaction, increasing its indirect holdings to 3,343,119 shares.
CapsoVision, Inc insider Harari Eliyahou et al, identified as a ten percent owner, reported an open-market purchase of 81,300 shares of common stock at $6.09 per share on July 8, 2026. The shares are held indirectly through the Harari Family Trust, where the reporting person and spouse serve as trustees, bringing the reported indirect holdings to 3,282,051 shares after this transaction.
CapsoVision, Inc insider holdings increased through an indirect open-market purchase. On June 26, 2026, the Harari Family Trust, for which the reporting person and his wife are trustees, bought 13,850 shares of CapsoVision common stock at $7.351 per share. After this transaction, the trust held 3,200,751 shares in total.
Shields David Stanley reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc director David Stanley Shields received a grant of 1,710 Restricted Stock Units (RSUs). The award was reported at a price of $0.0000 per unit, reflecting a compensation grant rather than a market purchase or sale.
Each RSU represents a contingent right to receive one share of CapsoVision common stock, and these RSUs are scheduled to vest on December 31, 2026. Following this grant, Shields is reported as directly holding 1,710 RSUs linked to common stock.
CapsoVision, Inc director Joanne Carol Imperial reported a routine equity compensation event. On June 30, she exercised previously granted Restricted Stock Units (RSUs), receiving 2,022 shares of common stock at no cash cost to her as part of an equity incentive grant.
The filing shows she now directly owns 3,709 shares of CapsoVision common stock. The RSU award was originally granted on March 19, 2026 using a fair market value of $6.18 per share, and vests in two installments each year, with this report reflecting the June 30 vesting portion.
CapsoVision, Inc director Joanne Carol Imperial reported an open-market sale of 1,200 shares of Common Stock on June 8, 2026 at an average price of $7.1555 per share. After this transaction, she directly holds 1,687 shares of CapsoVision stock.
The amended Form 4 notes that the filing is being made late because the company was not made aware of the reportable securities sale within the required timeframe.
CapsoVision director Tsai Chen Lung increased his direct equity stake through RSU vesting and option exercise. On June 30, he exercised derivative awards to acquire 2,022 shares of Common Stock at $7.58 per share. These shares came from Restricted Stock Units previously granted as part of equity incentive awards.
The RSUs were granted using a fair market value of $6.18 per share and vest 50% on June 30 and 50% on December 31 of the applicable year. This filing reflects vesting of one-half of the original RSU grant and delivery of the underlying shares. After the transactions, he holds 4,929 Common shares directly and 2,023 RSUs that remain outstanding.
CapsoVision, Inc director Kuo Hui Ying exercised restricted stock units to acquire 2,022 shares of common stock. The RSUs converted at a stated price of $7.58 per share, increasing the director’s direct common stock holdings to 15,263 shares following the transaction.
The RSUs were granted as part of equity incentive awards using a fair market value of $6.18 per share on March 19, 2026. The grant vests 50% of the RSUs on June 30 and 50% on December 31 of the applicable year, and this transaction reflects vesting of one-half of the original grant and receipt of the underlying shares, with 2,023 RSUs remaining outstanding.
CapsoVision, Inc director King Wen-Herng Henry exercised restricted stock units to acquire 2,022 shares of Common Stock on June 30, 2026. The shares were acquired at a reported transaction price of $7.58 per share through the conversion of RSUs granted as equity compensation.
The RSUs were originally granted on March 19, 2026 using a fair market value of $6.18 per share and vest in two equal installments, on June 30 and December 31 of the applicable year. This transaction reflects vesting of one-half of the original RSU grant and the delivery of the underlying shares.
Following the transaction, Henry directly holds 25,619 shares of CapsoVision common stock and 2,023 RSUs, indicating remaining unvested equity from the same or other awards.
CapsoVision director Michele Harari reported the vesting of equity incentives that converted into common stock. On June 30, 2026, 2,022 Restricted Stock Units (RSUs) converted into 2,022 shares of CapsoVision common stock at a stated price of $0.00 per share.
These RSUs were part of an equity incentive grant made on March 19, 2026, using a fair market value of $6.18 per share. After the transaction, Harari directly holds 61,065 shares of common stock and 2,023 RSUs that remain outstanding and unvested.
CapsoVision, Inc director Julia S. Gouw exercised Restricted Stock Units to acquire additional common shares as part of her equity compensation. On 2026-06-30, she converted 2,022 RSUs into 2,022 shares of common stock, an exercise classified as a derivative conversion rather than an open-market purchase or sale.
The RSUs were originally granted on 2026-03-19 using a fair market value of $6.18 per share and vest in two equal installments on June 30 and December 31 of the applicable year. This transaction reflects the vesting of one half of the original grant and the delivery of the underlying shares. Following the transaction, Gouw directly holds 4,909 common shares and 2,023 RSUs, highlighting a compensation-driven increase in her equity stake rather than a discretionary market trade.
CapsoVision, Inc director and officer Wang Kang-Huai received a grant of stock options covering 358,344 shares of common stock at an exercise price of $6.90 per share. The options were granted at no cost and expire on June 1, 2036.
The grant vests as to 25% of the options on June 1, 2027, with the remaining 75% vesting in 36 equal monthly installments through June 1, 2030, subject to continued service. Following this award, Wang holds 629,304 derivative securities directly.
CapsoVision, Inc reported that Sr. VP of Finance David Michael Garcia received a grant of stock options covering 92,212 shares of common stock. The options have an exercise price of $6.90 per share and expire on June 1, 2036.
The grant is compensation-related, with no cash changing hands at the time of grant. Following this award, Garcia holds options for a total of 257,212 underlying shares. According to the vesting terms, 25% of the options vest on June 1, 2027, and the remaining 75% vest in 36 equal monthly installments through June 1, 2030, subject to continued service.
CapsoVision, Inc granted stock options to its Head of Global Sales, Douglas Patrick Atkinson. He received options to buy 158,078 shares of common stock at an exercise price of $6.90 per share, expiring on June 1, 2036.
The options vest as to 25% of the shares on June 1, 2027, with the remaining 75% vesting in 36 equal monthly installments through June 1, 2030, subject to continued service. Following this award, Atkinson holds a total of 176,847 stock options directly.
CapsoVision, Inc Head of Global Sales Douglas Patrick Atkinson exercised stock options to acquire a total of 107,357 shares of common stock on May 4–5, 2026. The options were exercised at prices of $0.2863, $0.3663 and $0.5661 per share, with the exercise prices and share counts reflecting a 1‑for‑3.33 reverse stock split completed in connection with the company’s initial public offering. Following these exercises, he directly holds 107,357 common shares and retains 18,769 stock options with a $0.5661 exercise price expiring on July 23, 2033. No open‑market sales were reported in this filing.
Tsai Chen Lung reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. director Tsai Chen Lung reported receiving a grant of 4,045 Restricted Stock Units on March 19, 2026. Each RSU represents a contingent right to receive one share of CapsoVision common stock, giving him rights to 4,045 underlying shares after this award.
The RSUs vest in two equal installments, with 50% scheduled to vest on June 30, 2026 and the remaining 50% on December 31, 2026, subject to his continued service on the board through each vesting date. Following this grant, he holds 4,045 RSUs directly.
Kuo Hui Ying reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. reported that director Kuo Hui Ying received a grant of 4,045 Restricted Stock Units (RSUs), each representing one share of common stock. This is a compensation-related award rather than an open-market trade, and it brings the director’s reported holdings to 4,045 RSUs.
The RSUs vest in two equal parts: 50% on June 30, 2026 and 50% on December 31, 2026, conditioned on continued service on the board through each vesting date. No cash price was paid for the award.
King Wen-Herng Henry reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc director King Wen-Herng Henry reported receiving a grant of 4,045 Restricted Stock Units (RSUs) tied to the company’s common stock. Each RSU represents a contingent right to receive one share of common stock if vesting conditions are met.
The award is scheduled to vest in two equal tranches, with 50% vesting on June 30, 2026 and the remaining 50% vesting on December 31, 2026, subject to his continued service on the board through each vesting date. Following this grant, his reported direct holdings consist of 4,045 RSUs.
Imperial Joanne Carol reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc director Joanne Carol Imperial received a grant of 4,045 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of CapsoVision common stock.
The award vests in two equal installments: 50% on June 30, 2026 and 50% on December 31, 2026, subject to her continued service as a non-employee director through each vesting date. Following this grant, she holds 4,045 RSUs directly, and this filing reflects a compensation-related award rather than an open-market share purchase or sale.
Harari Michele reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. reported that director Michele Harari received a grant of 4,045 restricted stock units (RSUs), each representing the right to receive one share of common stock. The award is a form of equity compensation rather than an open-market purchase.
The RSUs are scheduled to vest in two equal installments, with 50% vesting on June 30, 2026 and the remaining 50% on December 31, 2026, subject to Harari’s continued service on the board through each vesting date. Following this grant, Harari holds 4,045 RSUs directly.
GOUW JULIA S reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. reported that director Julia S. Gouw received a grant of 4,045 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of CapsoVision common stock, so the grant covers 4,045 potential shares.
The RSUs vest in two equal tranches, with 50% scheduled to vest on June 30, 2026 and the remaining 50% on December 31, 2026. Vesting is conditioned on her continued service as a non-employee director on the board through each vesting date.
CapsoVision, Inc director Tsai Chen Lung reported an open-market purchase of common stock. A joint brokerage account for Tsai and his wife bought 20 shares of CapsoVision common stock at $4.17 per share on July 3, 2025. This Form 4/A is an amendment, filed because the transaction was inadvertently omitted from the original Form 4 submitted on July 7, 2025. After this trade, the account held 20 shares directly.
CapsoVision (CV) reported a Form 4 for David Garcia, Sr. VP of Finance. On 11/03/2025, he received a stock option grant for 165,000 shares at an exercise price of $4.78 per share, expiring 11/03/2035. The filing lists ownership of these derivative securities as direct.
The options vest as to 25% on November 3, 2026, with the remaining 75% vesting in 36 equal monthly installments through November 3, 2029, contingent on continued service.